MARKET

MDWD

MDWD

Mediwound
NASDAQ
8.85
-0.09
-1.01%
After Hours: 8.93 +0.08 +0.90% 16:00 12/01 EST
OPEN
8.96
PREV CLOSE
8.94
HIGH
8.96
LOW
8.76
VOLUME
17.85K
TURNOVER
0
52 WEEK HIGH
14.58
52 WEEK LOW
7.10
MARKET CAP
81.59M
P/E (TTM)
-5.0273
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at MDWD last week (1120-1124)?
Weekly Report · 5d ago
Mediwound’s Promising Outlook: Buy Rating Justified by Q3 Results and Expanding Market Opportunities
TipRanks · 11/23 16:05
Analysts’ Top Healthcare Picks: Aerovate Therapeutics (AVTE), Calidi Biotherapeutics (CLDI)
TipRanks · 11/22 11:20
Strong Buy Recommendation for Mediwound: Imminent Drivers, Promising Revenue Stream and Solid Financial Footing
TipRanks · 11/21 23:35
Mediwound: Report of foreign issuer
Press release · 11/21 17:07
Earnings Scheduled For November 21, 2023
Golden ocean group is likely to report quarterly earnings at $0.11 per share on revenue of $149.42 million. Singing machine co is expected to report earnings for its second quarter. Apple is projected to report its third quarter earnings before the bell on friday.
Benzinga · 11/21 12:12
MediWound Q3 2023 Earnings Preview
Mediwound ltd. Is scheduled to announce q3 earnings results on november 21st. The consensus eps estimate is -$0.39 and the consensus revenue estimate is $4.75 million. Mdwd has beaten eps estimates 38% of the time in the last 2 years.
Seeking Alpha · 11/20 17:56
Earnings Outlook For MediWound
Mediwound is set to give its quarterly earnings report on 2023-11-21. Analysts estimate the company will report an earnings per share of $-0.44. Last quarter the company beat eps by $0.51, but the share price dropped 1.54%. Shares of the company are down 22.68% in the last 52 weeks.
Benzinga · 11/20 15:01
More
About MDWD
Mediwound Ltd is an Israel-based biopharmaceutical company that develops, manufactures and commercializes novel, cost effective, bio-therapeutic solutions for tissue repair and regeneration. Company's portfolio is focused on next-generation protein-based therapies for burn and wound care and tissue repair and includes products such as, NexoBrid, a concentrate of proteolytic enzymes enriched in bromelain, which is an easy to use, topically-applied product that removes eschar in four hours without harming the surrounding healthy tissues.; EscharEx biological drug candidate for the debridement of chronic and other hard-to-heal wounds; MW005 a topically applied biological drug candidate for the treatment of non-melanoma skin cancers, based on the same API of NexoBrid and EscharEx products, a concentrate of proteolytic enzymes enriched in bromelain.

Webull offers Mediwound Ltd stock information, including NASDAQ: MDWD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MDWD stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading MDWD stock methods without spending real money on the virtual paper trading platform.